eMESH Struct. 2022-23 (eMESH)

  • End date
    Aug 9, 2023
  • participants needed
  • sponsor
    Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Updated on 4 October 2022
Accepts healthy volunteers


A flexible energy metabolism matched with the contractile needs of the muscle is essential to a normal heart. Loss of metabolic flexibility and cardiac systolic efficiency coexist in Sepsis-induced Myocardial Dysfunction (SIMD), a phenomenon attributed to mitochondrial dysfunction and mishandling of energy substrates. Cardiac positron emission tomography (PET) could allow to quantify non invasively the selection of energy substrates by the hearts in sepsis and will be associated in parallel with functional status (ultrasound cardiography), injury biomarkers, apelinergic and metabolomic blood profiles. Comparisons will be performed between septic and acute on chronic heart failures, with or without systolic dysfunction.


Septic shock is both highly prevalent and morbid in the intensive care units. The mortality rate rises from 10-30% to 70-80% with sepsis-induced myocardial dysfunction (SIMD) occurence. SIMD is related to stress-induced cardiomyopathies and features bio-mechanistic components distinctive from chronic heart failure (CHF) traditionally attributed to a coronary disease. Dobutamine, a beta-adrenergic receptor agonist, is the inotrope drug actually recommended when cardiac index is too low, often in association with a mix of alpha-beta-adrenergic agonists like norepinephrine. In this context, dobutamine is marginally effective (1/3 responders), has potential deleterious impacts on function and viability of cardiomyocytes, and induces increased needs in cardiac energy metabolism. The healthy heart works almost exclusively on aerobic metabolism. While glucose is the essential fuel for brain and skeletal muscles, fatty acids through lipid oxidation are the main substrates for a normal resting heart (Randle cycle). This lipid oxidation is producing at least 70% of cardiac ATP, the balance is coming from glucose, with a marginal contribution from ketone bodies and lactate. The mitochondria is a cellular factory which produces more than 95% of body ATP. Mitochondria represent 30-40% of the cardiomyocyte total volume and consume oxygen to generate huge quantities of ATP/day by oxidative phosphorylation through 3 connective pathways: cytoplasmic glycolysis, Krebs cycle, and the mitochondrial electron transport chain inside the respiratory enzymes complex. Although a direct close relationship between myocardial metabolism homeostasis and function is not clearly established in normal condition, a compensatory equilibrium between fatty acid and glucose mitochondrial oxidations is a generally accepted concept. Indeed, the heart is omnivorous and can modulate fuel-substrates captation/utilization according to the physiological events (exercise, fast).That reprogramming capacity towards other various circumstances or pathological conditions is not guaranteed, with potential loss of metabolic flexibility. SIMD is highly prevalent in septic shock and is frequently indicative of a worsened outcome with increased mortality. Left ventricular systolic and diastolic dysfunctions are observed in 50% of acute sepsis within the first 48 hours after patient's admission. Animal experimental models can simulate human sepsis and SIMD by injecting endotoxin (LPS model) or feces in the abdominal cavity (cecal ligation puncture model), and with inflammatory cytokines, oxidative stress, nitric oxide and neutrophils as potential aggressors. Ventriculo-arterial and excitation-contraction decoupling are the hallmark of the contractile inefficiency observed in SIMD. Ca2+ handling (an ion molecule essential for heart function) in aberrant during sepsis and associated with impaired activation/phosphorylation and proteolytic cleavage increased of key regulators like heart troponin I. Resulting common cyto-histopathological damages are: myocardial apoptosis with focal necrosis, cardiac muscle edema, congestion, multiples inflammatory infiltrates, and mitochondrial structural insults with intra-myocardial accumulation of glycogen & lipids. The lathers could be a spillover effect of the cardiac metabolic shut-down consecutive to mitochondrial dysfunction. A decrease in fatty acid captation/oxidation has been documented in traditional CHF, not always offset by an enhanced use of glucose, but sometimes by an increased use of ketone bodies and lactates, and through an elevated myocardial proteolysis. This observation doesn't necessarily apply to sepsis and SIMD where cardiac energy metabolism is still a mystery. Systemic metabolic alterations in sepsis are complexe, with glycogenolysis and gluconeogenesis activations, insulinoresistance, and an increased lipolysis with enhanced fatty acid blood levels. In these conditions and in the heart, a drop of fatty acid oxidation is not necessarily compensated by an increased glucose use. Different denominations have been used to figure out these SIMD-induced metabolism disorders, the best being "metabolic-bioenergetic shut-down and stunning". In fact, sepsis induces a metabolic hurricane in bloodstream, vital organs and mitochondria, resulting in a significant rise of the rest energy expenditure. Dhainaut et al were first to demonstrate in 1987 a shift in the selection of energy fuels by myocardial tissues in septic shock patients. Both fatty acid and glucose uses were diminished by 4 and 2 times, respectively. However, this study addressed to suboptimally fluid resuscitated patients, who were in early acute hyperdynamic shock (< 6 hours). In experimental mouse models challenged with LPS or cecal ligation puncture, and adequate fluid resuscitation, the cardiac microperfusion is altered (i.e. malperfusion), and mitochondrial oxidative metabolism diminished, with an increase of glucose myocardial uptake. The apelin system is a family of endogenous peptides hormones (the apelins), not related to catecholamines, but with strong cardiovascular properties. This functional impact correlates with the constitutive expression of apelins and their receptor APJ in heart and vessels. Cardiac effects of apelins are characterized by an enhanced contractile force (systolic function), without chronotropic but with a lusitropic effect and a dromo-modulation. Another one impact of the apelins is on the cardiac utilization of metabolic energy substrates.

Apelins are facilitators-influencers glucose and fatty acid usage through recruitment of major specific carriers such as GLUT4 and FAT/CD36.

Research investigations: Which energy source is privileged by cardiac mitochondria in acute septic shock with or without myocardial dysfunction vs non-septic CHF ? Is this tentative shift/move of energy substrate's use related to muscle dysfunction or only reactive to the systemic environment ? and is it specific of sepsis or common to any non-specific myocardial damage ? Is this shift related to a particular biophenotype of the apelinergic system which is involved in the cardiovascular homeostasis ? and/or a distinctive alteration of the cardiac injury biomarkers ? Is the systemic environmental metabolomic affected toward a trending way during acute septic shock ?

Hypotheses: A myocardial positron emission tomography (PET) could allow to visualize and quantify non invasively energy supply selection of hearts in acute shock conditions related or not related to sepsis. Relationships can be found between PET profiles, sources of acute shock (sepsis vs non sepsis), functional data (ultrasound cardiography), cardiac injury specific biomarkers, apelinergic and metabolomic blood profiles.

Objectives: 1) To show the analytical value of the cardiac captation kinetic of 3 energy tracers (palmitate for fatty acids, FDG for glucose and acetate fpr mitochondrial activity), 2) To correlate PET data with myocardial (dys)function observed by US cardiography, 3) To evaluate the patients blood metabolomic profile in terms of products accumulation derived from a failure of energy substrates oxidation, 4) To measure and compare myocardial injury/ remodelling biomarkers (troponins, NT-proBNP, galectin-3) and the systemic endogenous apelin biophenotype.

Methods: 1) Prospective evaluative study of 4 groups of 8 patients in septic shock or in acute heart failure under hemodynamic support: i) a group with evidences of SIMD (US cardiography at the ICU ward in the first 48hrs: systolic ejection fraction < 45%), ii) a group in septic shock without evidence of SIMD, iii) a group with non-septic heart failure (systolic ejection fraction < 45% or cardiac insufficiency with reduced ejection fraction, iv) a group with non-septic (systolic ejection fraction < 50% or cardiac insufficiency with reduced ejection fraction.

Condition Septic Shock, Chronic Heart Failure
Treatment blood sampling, FDG PET scan, ultrasound cardiography, Palmitate PET scan, Acetate PET scan
Clinical Study IdentifierNCT05202938
SponsorCentre de recherche du Centre hospitalier universitaire de Sherbrooke
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Patients hospitalized in intensive care unit and coronary unit of the Sherbrooke hospital/CHUS
Accepts healthy volunteers: 4 to 6 age- and sex-matched HV will be recruited and imaged at the end of the inclusion window for the assessment of cardiac energy tracer's uptake and as ref. controls

Exclusion Criteria

Pediatric patients
Albumin allergy
Moribund patients
Patients too much unstable for the imaging procedure (clinical judgment)
Unavailable tracers, staff, PET scan in a maximum delay of 72 hours
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note